I

Ionis Pharmaceuticals
D

IONS

31.440
USD
-0.82
(-2.54%)
مغلق
حجم التداول
47,072
الربح لكل سهم
-3
العائد الربحي
-
P/E
-13
حجم السوق
4,964,290,703
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ACAD
    0.035
    (0.20%)
    17.560 USD
    ALNY
    ALNY
    -2.740
    (-1.10%)
    246.360 USD
    BIIB
    BIIB
    -0.660
    (-0.47%)
    140.580 USD
    B
    BMRN
    0.260
    (0.42%)
    61.570 USD
    C
    CRSP
    0.260
    (0.65%)
    40.520 USD
    GILD
    GILD
    0.150
    (0.16%)
    91.790 USD
    REGN
    REGN
    -11.37
    (-1.64%)
    681.49 USD
    S
    SRPT
    1.070
    (0.91%)
    118.040 USD
    VRTX
    VRTX
    4.97
    (1.19%)
    422.10 USD
    المزيد
الأخبار
المقالات

العنوان: Ionis Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.